Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
Thomas Yul Avery, Natalie Köhler, Robert Zeiser, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Novel small molecule inhibitors targeting renal cell carcinoma: Status, challenges, future directions
Lin Xiong, Ya Zhang, Jiaxing Wang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116158-116158
Open Access | Times Cited: 10
Genomic profiling in GIST: Implications in clinical outcome and future challenges
G. Calderillo-Ruiz, Eloy-Andrés Pérez-Yépez, M. García-Gámez, et al.
Neoplasia (2024) Vol. 48, pp. 100959-100959
Open Access | Times Cited: 9
The Role of the Gut Microbiota in Modulating Signaling Pathways and Oxidative Stress in Glioma Therapies
Aleksandra Krawczyk, Gabriela Elzbieta Sladowska, Barbara Strzałka‐Mrozik
Cancers (2025) Vol. 17, Iss. 5, pp. 719-719
Open Access | Times Cited: 1
Targeting Cell Signaling Pathways in Lung Cancer by Bioactive Phytocompounds
Neeraj Choudhary, Sweta Bawari, Jack T. Burcher, et al.
Cancers (2023) Vol. 15, Iss. 15, pp. 3980-3980
Open Access | Times Cited: 19
Mcl-1 Protein and Viral Infections: A Narrative Review
Zbigniew Wyżewski, Justyna Stępkowska, Aleksandra Maria Kobylińska, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1138-1138
Open Access | Times Cited: 5
Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer
Wei Ye, Lu Xin, Yue Qiao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 3, pp. 189108-189108
Closed Access | Times Cited: 5
Combination therapy with immune checkpoint inhibitors in colorectal cancer: Challenges, resistance mechanisms, and the role of microbiota
Ali Rahimi, Zeinab Baghernejadan, Ali Hazrati, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 186, pp. 118014-118014
Closed Access
PD-L1 Inhibitor Cosibelimab for Cutaneous Squamous Cell Carcinoma: Comprehensive Evaluation of Efficacy, Mechanism, and Clinical Trial Insights
Omer A. Idris, Diana Westgate, Bahar Saadaie Jahromi, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 889-889
Open Access
Immune checkpoint blockade therapy for BRAF mutant metastatic colorectal cancer: the efficacy, new strategies, and potential biomarkers
Jie Zhong, Zijian Sun, Sheng Li, et al.
Discover Oncology (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 11
A neutral polysaccharide from Persicaria hydropiper (L.) Spach ameliorates lipopolysaccharide-induced intestinal barrier injury via regulating the gut microbiota and modulating AKT/PI3K/mTOR and MAPK signaling pathways
Xuanxuan Cheng, Yuehua Zhu, Jiahuan Huang, et al.
Journal of Ethnopharmacology (2023) Vol. 320, pp. 117403-117403
Closed Access | Times Cited: 10
An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer
Sankha Bhattacharya
Critical Reviews in Oncology/Hematology (2023) Vol. 183, pp. 103916-103916
Closed Access | Times Cited: 9
Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study
Dong Hyun Kim, Seung Taek Lim, Hye Ryun Kim, et al.
Oral Oncology (2024) Vol. 151, pp. 106739-106739
Closed Access | Times Cited: 3
Colorectal Cancer with BRAF V600E Mutation: Trends in Immune Checkpoint Inhibitor Treatment
Mengling Liu, Qing Liu, Keshu Hu, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 204, pp. 104497-104497
Closed Access | Times Cited: 3
Interaction between CD244 and SHP2 regulates inflammation in chronic obstructive pulmonary disease via targeting the MAPK/NF-κB signaling pathway
Xiao‐Bing Gao, Shengli Shao, Xi Zhang, et al.
PLoS ONE (2024) Vol. 19, Iss. 10, pp. e0312228-e0312228
Open Access | Times Cited: 2
Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition
Mora Guardamagna, Miguel‐Ángel Berciano‐Guerrero, Beatriz Villaescusa-González, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11990-11990
Open Access | Times Cited: 11
SOS1-inspired hydrocarbon-stapled peptide as a pan-Ras inhibitor
Anpeng Li, Xiang Li, Jihua Zou, et al.
Bioorganic Chemistry (2023) Vol. 135, pp. 106500-106500
Closed Access | Times Cited: 6
SHED‐exos promote saliva secretion by suppressing p‐ERK1/2‐mediated apoptosis in glandular cells
Wei‐Xia Chu, Chong Ding, Zhi‐Hao Du, et al.
Oral Diseases (2023) Vol. 30, Iss. 5, pp. 3066-3080
Open Access | Times Cited: 6
Synthetic RIG-I agonist-mediated cancer immunotherapy synergizes with MAP kinase inhibition against BRAF-mutated melanoma
Christian Grützner, Yu Pan Tan, Patrick Müller, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 35, Iss. 3, pp. 102283-102283
Open Access | Times Cited: 1
Immune check point inhibitors in BRAF mutated metastatic colorectal cancer: A review
Alfredo Colombo, Stefano Cordio, Concetta Maria Porretto
International Journal of Gastrointestinal Intervention (2024) Vol. 13, Iss. 3, pp. 74-81
Open Access | Times Cited: 1
Reprogramming Tumor-Associated Macrophages: The Role of MEK-STAT3 Inhibition in Lung Cancer
Sushama Rawat, Ehssan Moglad, Muhammad Afzal, et al.
Pathology - Research and Practice (2024) Vol. 265, pp. 155748-155748
Closed Access | Times Cited: 1
Association of Neurokinin-1 Receptor Signaling Pathways with Cancer
Francisco D. Rodríguez, Rafael Coveñas
Current Medicinal Chemistry (2023) Vol. 31, Iss. 39, pp. 6460-6486
Closed Access | Times Cited: 3
Targeted therapy based on ubiquitin-specific proteases, signalling pathways and E3 ligases in non-small-cell lung cancer
Yuchen Yang, Canjun Zhao, Zhao-Feng Jin, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 2
The utility of molecular studies on pancreatic cystic lesions: A comprehensive review
Rong Xia, Xiaoying Liu, Cristina Hajdu, et al.
Human Pathology Reports (2024) Vol. 36, pp. 300741-300741
Open Access
Incorporating histone H2B variants into chromatin modifies chromatin accessibility to induce epithelial-to-mesenchymal transition in breast cancer
Héjer Dhahri, Kin H. Lau, Wesley N. Saintilnord, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
A Narrative Review of the Role of Immunotherapy in Metastatic Carcinoma of the Colon Harboring a BRAF Mutation
Alfredo Colombo, PORRETTO MARIA CONCETTA, Vittorio Gebbia, et al.
In Vivo (2024) Vol. 39, Iss. 1, pp. 25-36
Open Access
Page 1 - Next Page

Scroll to top